Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q1 2018 · 10-Q
Revenue$178.58K$178.58K−26.4% vs Q1 2017 Net Income-$381.55K-$381.55KN/M vs Q1 2017 EPS Diluted-$0.46-$0.46N/M vs Q1 2017 Operating Income-$8,282,820N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,412,487N/M Margins · derivedOperating margin-4638.1%−1197.0 pt vs Q1 2017
Net margin-213.7%+3195.3 pt vs Q1 2017
ended Mar 31, 2018 · filed May 2, 2018 · 32 d after period end